

a) at least a portion of the adeno-associated virus genome;

b) at least one eukaryotic based *cis*-acting regulatory sequence; and

c) at least one eukaryotic based nucleic acid sequence that encodes a therapeutic [protein] gene product, said virus vector having the property of regulating cell specific expression of said nucleic acid sequence or nucleic acid sequences upon stable transduction of a target mammalian cell.

27. (amended) A recombinant adeno-associated virus vector, which comprises:

a) at least a portion of the adeno-associated virus genome;

b) a eukaryotic based *cis*-acting regulatory sequence; and

c) a eukaryotic based nucleic acid sequence that encodes a therapeutic [protein] gene product, said virus vector having the property of regulating cell specific expression of said nucleic acid sequence or nucleic acid sequences upon stable transduction of a human hematopoietic cell.

REMARKS

Claims 1-35 and 39 are pending in this application. Applicants submit herewith a new Rule 132 Declaration executed by the declarant, Dr. Richard Jude Samulski.

Claims 1 and 27 have been amended to recite that the recombinant adeno-associated viral vectors encode a